Content about Growth hormone

April 9, 2013
Sierra Research Labs issues third license to amino acid compound amid increased demand

The developer of an amino acid compound is issuing a new license for the product.

NEW YORK — The developer of an amino acid compound is issuing a new license for the product.

March 25, 2013
SanMedica unveils new HGH-booster at Academy of Women's Health's Annual Congress

SanMedica International introduced its SeroVital-HGH, a new oral human-growth hormone booster formulated with women in mind, at the Academy of Women's Health's Annual Congress.

WASHINGTON —  SanMedica International on Friday introduced its SeroVital-HGH, a new oral human-growth hormone booster formulated with women in mind, at the Academy of Women's Health's Annual Congress here. 

December 27, 2012
Sierra Research Labs licenses distribution of SeroVital-hgh through GNC to Novex Biotech

Demand for SeroVital-hgh — a proprietary amino acid compound developed by Sierra Research Labs — has spiked in the past month. To help meet demand, the company on Dec. 21 announced distribution expansion through GNC.

NEW YORK — Demand for SeroVital-hgh — a proprietary amino acid compound developed by Sierra Research Labs — has spiked in the past month, in part due to recent exposure on news channels like CNN and on news programs like "The Today Show," the company announced last week. To help meet demand, the company on Dec. 21 announced distribution expansion through GNC. 

October 11, 2011
ReportersNotebook — Chain Pharmacy, 10/10/11

The Food and Drug Administration has approved Mylan’s promethazine hydrochloride tablets, a generic drug for treating allergies, in the 12.5-mg, 25-mg and 50-mg strengths.

SUPPLIER NEWS — The Food and Drug Administration has approved Mylan’s promethazine hydrochloride tablets, a generic drug for treating allergies, in the 12.5-mg, 25-mg and 50-mg strengths. Promethazine hydrochloride tablets, which are manufactured by several companies, had sales of about $42 million during the 12-month period ended in June, according to IMS Health.


September 1, 2011
Omnitrope approved for Turner syndrome

The Food and Drug Administration has approved a new use for a follow-on biologic made by Sandoz.

PRINCETON, N.J. — The Food and Drug Administration has approved a new use for a follow-on biologic made by Sandoz.

Sandoz, the generic drugs arm of Swiss drug maker Novartis, announced the approval of Omnitrope (somatropin [rDNA origin]) for children with growth failure due to Turner syndrome. Sandoz said Omnitrope was now approved for all the same indications as the reference product, Pfizer's Genotropin.

January 18, 2011
Sandoz commences mid-stage trial for Rituxan biosimilar

Generic drug maker Sandoz has started a mid-stage clinical trial of a monoclonal antibody used to treat cancer and autoimmune disease, the company said.

HOLZKIRCHEN, Switzerland — Generic drug maker Sandoz has started a mid-stage clinical trial of a monoclonal antibody used to treat cancer and autoimmune disease, the company said.

Sandoz (pronounced “SAN-doh”), the generics arm of Swiss drug maker Novartis, announced the start of a phase-2 trial of rituximab, a biosimilar of Genentech’s Rituxan, used to treat such conditions as non-Hodgkin’s lymphoma and rheumatoid arthritis.

November 10, 2010
Egrifta receives regulatory approval

The Food and Drug Administration has approved a drug for treating excess fat development in...

SILVER SPRING, Md. The Food and Drug Administration has approved a drug for treating excess fat development in patients with HIV, the agency said Thursday.

 

The FDA approved Egrifta (tesamorelin) for treating HIV patients with lipodystrophy, a condition in which excess fat develops in different areas of the body, such as the abdominal organs. The condition is often a side effect of the retroviral drugs used to treat the disease.

 

 

August 26, 2010
FDA approves new use of first U.S.-approved follow-on biologic

The FDA approved Sandoz Omnitrope (somatropin [rDNA origin]) as a treatment for idiopathic short stature,...

June 27, 2010
FDA approves expanded use of Omnitrope

The Food and Drug Administrations has approved two new uses for what remains, thus far,...

March 2, 2010
Norditropin FlexPro receives FDA approval

The Food and Drug Administration has approved a Novo Nordisk treatment for growth hormone disorders,...